A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
DRUG: TQ-B3525 tablets
Overall response rate (ORR) assessed by Independent Review Committee, Percentage of participants achieving complete response (CR) and partial response (PR) based on IRC, Baseline up to 18 months
Overall response rate (ORR) assessed by Investigator, Percentage of participants achieving complete response (CR) and partial response (PR) assessed by investigator., Baseline up to 18 months|Duration of disease remission (DOR), The time from the first evaluation of the subject as CR or PR to the first evaluation of the subject as PD or death (whichever occurs first)., Baseline up to 18 months|Progression-free survival (PFS), PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause, Baseline up to 18 months|Disease control rate（DCR）, Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD)., Baseline up to 18 months|Overall Survival (OS), OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up., Baseline up to 24 months|Incidence of Adverse Events, Serious Adverse Events, AE, SAE, and withdrawal from the trial for reasons such as safety or tolerability., Baseline up to 18 months
This is a study to evaluate the efficacy and safety of TQ-B3525 in subjects with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.